Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GSK217744 Booster in Toddlers
NCT01453998Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 2011
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2 trial of Infanrix Hexa in diphtheria, Tetanus, pertussis and 3 more (3 arms), sponsored by GSK. Primary endpoints: Number of Seroprotected Subjects for Anti-diphtheria and Anti-tetanus Antibodies, Number of Seroprotected Subjects Against Anti-Hepatitis B Antigens and 3 more. Started Oct 2011; status: completed.
02
Drugs
Infanrix Hexa
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)poliomyelitis
Beyond the preview
Go deeper on NCT01453998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01453998.